The evolution of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …
A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19
Z Cao, W Gao, H Bao, H Feng, S Mei… - … England Journal of …, 2023 - Mass Medical Soc
Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …
individuals,–. Despite the reduced protection from infection, individuals who received three …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
[HTML][HTML] Mechanisms of SARS-CoV-2 entry into cells
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
Early remdesivir to prevent progression to severe Covid-19 in outpatients
RL Gottlieb, CE Vaca, R Paredes, J Mera… - … England Journal of …, 2022 - Mass Medical Soc
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …
The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …